Education
About Us
Working with TipRanks
Follow Us
Maravai Lifesciences Holdings (MRVI)
NASDAQ:MRVI
Top Page
Maravai Lifesciences Holdings
(NASDAQ:MRVI)
Select Model
Select Model
Rating:53Neutral
Price Target:
$3.50
▼(-1.69% Downside)
Action:ReiteratedDate:02/27/26
The score is held back primarily by weak recent financial performance (steep revenue decline, large losses, and 2025 cash burn) despite improved leverage. Offsetting this, the latest earnings call provided comparatively strong turnaround signals (positive 2026 EBITDA outlook and sizable cost reductions) and the technical trend is moderately constructive with price above major moving averages.
Positive Factors
Leverage Reduction
A dramatic reduction in debt meaningfully lowers interest burden and financial risk, providing management durable balance-sheet flexibility. This creates runway to invest in product commercialization, sustain operations through recovery, and reduces refinancing pressure over the next several quarters.
Structural Cost Savings
Exceeding >$65M in annualized cost reductions materially lowers the company's operating expense base. These permanent reductions improve operating leverage, support sustained margin expansion and make the 2026 adjusted EBITDA recovery more durable even if revenue growth is modest.
High‑Margin Segment Cash Flow
Cygnus' very high adjusted EBITDA margin and steady growth provide a reliable, high‑quality cash generator within the portfolio. This segment supplies durable internal cash flow and margin stability that can subsidize investments and buffer volatility in other, lumpier businesses.
Negative Factors
Cash Burn / Weak Cash Flow
A sustained swing to materially negative operating and free cash flow constrains reinvestment and heightens reliance on external financing or asset sales to fund operations. Persistent cash burn weakens resilience and makes execution of the turnaround contingent on swift cash conversion.
Severe Revenue Contraction
A ~74% revenue collapse dramatically reduces scale, dilutes fixed-cost coverage, and erodes pricing and supplier leverage. Restoring historical margins requires sustained multi‑period top‑line recovery; prolonged revenue weakness threatens the viability of prior operating models.
Large GAAP Charges and Impairments
Material noncash impairments and restructuring charges produce large GAAP losses and reduce shareholder equity. These write‑downs signal lasting asset base impairment, compress book value, and can impair investor confidence and future ability to raise capital on favorable terms.
Maravai Lifesciences Holdings (MRVI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$910.32M
Dividend YieldN/A
Average Volume (3M)1.02M
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth-30.56%
EPS Growth48.79%
CountryUS
Employees570
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding145,022,750
10 Day Avg. Volume1,087,304
30 Day Avg. Volume1,022,877
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)2.22
Price to Sales (P/S)2.54
P/FCF Ratio-6.67
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue4.31
Enterprise Value/Gross Profit23.57
Enterprise Value/Ebitda-5.09
Forecast
1Y Price Target
$4.13Price Target Upside16.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.2
Revenue Forecast (FY)$203.40M
Maravai Lifesciences Holdings Business Overview & Revenue Model
Company DescriptionMaravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
How the Company Makes MoneyMaravai Lifesciences generates revenue through multiple streams, primarily by providing high-quality nucleic acid products and services to biotechnology and pharmaceutical companies, academic institutions, and contract research organizations. Key revenue streams include sales of custom oligonucleotides, RNA production, and reagents for molecular biology applications. The company also benefits from partnerships with major players in the biopharmaceutical industry, enhancing its market position and driving sales growth. Furthermore, the increasing demand for mRNA-based therapeutics and vaccines, particularly highlighted during the COVID-19 pandemic, has contributed significantly to Maravai's earnings, as its products are pivotal in the development and manufacturing of these innovative therapies.
Maravai Lifesciences Holdings Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyMaravai Lifesciences Holdings Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Positive
The call conveyed a clear operational turnaround: management exceeded cost-savings targets (> $65M), returned to positive adjusted EBITDA in Q4, and provided constructive 2026 guidance (revenue growth and a materially positive adjusted EBITDA outlook). Product momentum (ModTail, GMP enzymes, mRNAbuilder, IVT kits) and Cygnus' strong margins were highlighted as durable strengths. Headwinds remain, including sizable GAAP losses driven by impairment and restructuring charges, continued full-year negative adjusted EBITDA in 2025, outstanding leverage, and order lumpiness that can produce volatility. Overall, the tone is optimistic about returning to sustained profitability in 2026 while acknowledging near-term balance-sheet and GAAP earnings challenges.Q4-2025 Updates
Positive Updates
Full-Year Revenue and Q4 Performance
Full-year 2025 revenue of $185.7M (beat guidance by ~$0.7M). Q4 2025 revenue $49.9M; excluding $14.3M of high-volume CleanCap sales in Q4 2024, Q4 revenue grew 18% year-over-year.
Return to Positive Adjusted EBITDA
Company delivered positive adjusted EBITDA of $0.536M in Q4 2025 (first positive adjusted EBITDA in four quarters), an improvement of ~$11M sequentially from Q3 and versus negative $1.1M in Q4 2024.
Exceeded Cost Savings Target
Restructuring and cost actions exceeded prior target of >$50M annualized savings; management now estimates >$65M of annualized savings (captured ~$3M in Q3 and ~$8M in Q4).
Strong Cygnus Profitability and Growth
Cygnus Q4 revenue $15.3M (up 4% YoY); Q4 adjusted EBITDA $10.2M representing a 66.7% margin. Full-year Cygnus revenue $66M (+5% YoY) with adjusted EBITDA $44.2M (67% margin).
TriLink Underlying Growth (Ex-CleanCap)
TriLink Q4 revenue $34.6M (down 17% YoY overall; excluding $14.3M COVID CleanCap comp in Q4 2024, base TriLink revenue grew 25% YoY). TriLink Q4 adjusted EBITDA $0.936M.
Product and Commercial Traction
ModTail launched in H2 2025 generated >$0.5M in 2025 and has already exceeded that level in 2026 YTD bookings; mRNAbuilder platform has processed ~70 orders; new IVT kit received >100 orders in first weeks; GMP enzymes orders of >$1.2M in hand for 2026.
2026 Financial Guidance Indicates Turnaround
Guidance for 2026: revenue $200M–$210M (growth 8%–13%); expected full-year adjusted EBITDA $18M–$20M (improvement of ~$50M–$52M vs 2025); projected ~1,200 bps gross margin expansion and operating expense reductions (OpEx -13%, G&A -18%).
Balance Sheet and Debt Reduction Action
Year-end cash $216.9M and long-term debt $294.2M. Company made a voluntary $50M debt repayment in Q1 2026, reducing both cash and debt to lower interest expense.
Corporate and Legal Risk Remediation
Completed implementation of internal controls remediation for previously identified material weaknesses; U.S. District Court dismissed securities class action lawsuits in full.
Negative Updates
Large GAAP Net Losses and Impairment Charges
Q4 2025 GAAP net loss before noncontrolling interest was $63M (vs $46.1M in Q4 2024), which included a $25.8M noncash intangible asset impairment and $12.1M of noncash restructuring charges. Full-year GAAP net loss was $230.8M (vs $259.6M in 2024).
Full-Year Adjusted EBITDA Still Negative
Adjusted EBITDA for full-year 2025 remained negative $31.2M (improved from negative $35.9M in 2024), indicating profitability progress but continued full-year non-GAAP loss.
Earnings Per Share Deterioration (GAAP and Adjusted Mixed)
Q4 basic and diluted loss per share was $0.24 (worse than $0.18 in Q4 2024). Adjusted EPS for Q4 was a loss of $0.04 (improvement vs $0.06), but full-year adjusted fully diluted EPS was a loss of $0.29 (worse vs $0.10 prior year).
High Leverage and Cash Burn in Quarter
Long-term debt was $294.2M at year-end with cash used in operations of $22.8M in Q4 (including $3.6M restructuring). Although a $50M voluntary debt repayment was made in Q1 2026, leverage and cash flow remain material considerations.
Business Lumpiness and Order Volatility
Management highlighted inherent lumpiness (average order cycle ~6 months) and variability tied to program progression; this creates forecasting uncertainty despite improved visibility and higher early-period orders.
One-Time and Noncash Charges Impact GAAP Results
Significant noncash items (goodwill/intangible impairment, restructuring, lease unwind costs) materially depressed GAAP profitability in Q4 2025.
Segment Yearly Weakness at TriLink (Including COVID Comps)
TriLink full-year adjusted EBITDA was negative $23.1M and TriLink annual revenue declined 8% excluding high-volume CleanCap revenue, reflecting continued recovery needed in some areas.
Company Guidance
Management guided 2026 revenue of $200–$210 million (up 8–13% vs. 2025’s $185.7M), with TriLink targeting low‑double‑digit growth at the midpoint and Cygnus low‑ to mid‑single‑digit growth, and full‑year adjusted EBITDA of $18–$20 million (an improvement of $50–$52M versus 2025). They expect roughly 1,200 basis points of gross margin expansion, total operating expenses down ~13%, G&A down ~18%, sales & marketing down ~13% and modestly higher R&D; modeling assumptions include net interest expense of $15–$17M, depreciation & amortization of $50–$52M, stock‑based compensation of $26–$28M, fully converted share count ~261M and net capex of $4–$6M. Management also noted they exceeded their cost‑saving target (now >$65M annualized vs. prior >$50M), reported Q4 adjusted EBITDA of $0.536M, expect positive adjusted EBITDA and positive cash flow in 2026, and executed a voluntary $50M debt repayment in Q1 (after year‑end cash of $216.9M and long‑term debt of $294.2M).Maravai Lifesciences Holdings Financial Statement Overview
Summary
Overall fundamentals are pressured: revenue has contracted sharply (including ~74% drop in 2025 vs 2024), margins compressed materially, and profitability remains deeply negative with negative operating and free cash flow in 2025. A notable offset is the improved leverage profile from the sharp reduction in debt in 2025, but shrinking equity and continued losses keep financial risk elevated.Income Statement
The income statement shows a sharp deterioration in scale and profitability. Revenue fell materially in 2025 versus 2024 (down ~74%), following declines in 2023 and 2024, signaling a multi-year contraction. Margins also weakened: gross margin compressed to ~26% in 2025 from ~42% in 2024 and ~81–82% in 2021–2022. Profitability is deeply negative, with a very large net loss in 2025 (net margin roughly -262%), indicating significant costs and/or charges relative to the reduced revenue base. The key strength is historical profitability in 2020–2022, but the most recent two years show substantial pressure and volatility.22
Negative
Balance Sheet
The balance sheet looks mixed but has recently improved on leverage. Total debt dropped sharply in 2025 to ~$36M from ~$377M in 2024, bringing debt-to-equity down to ~0.17x (from ~1.16x in 2024 and ~1.47x in 2023), which reduces financial risk. However, equity declined from ~$325M (2024) to ~$212M (2025), and returns on equity are meaningfully negative in 2023–2025, consistent with ongoing net losses and pressure on book value. Overall: stronger leverage profile in the latest year, but weakened shareholder returns and shrinking capital base are clear offsets.56
Neutral
Cash Flow
Cash flow trends have turned negative and less dependable. Operating cash flow swung from positive in 2023 (~$126M) to slightly positive in 2024 (~$7M) and then materially negative in 2025 (~-$58M), indicating the business is consuming cash in operations. Free cash flow also deteriorated from strongly positive in 2022–2023 to negative in 2024 and 2025 (about -$71M in 2025). A positive point is that free cash flow was less negative than net income in 2025 (free cash flow to net income > 1), implying non-cash losses are significant, but the core issue remains: recent cash burn and weaker cash generation compared with earlier years.30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 49.87M | 259.19M | 288.94M | 883.00M | 799.24M |
| Gross Profit | 12.84M | 108.31M | 140.20M | 714.04M | 658.68M |
| EBITDA | -223.02M | -156.92M | 712.41M | 609.99M | 585.78M |
| Net Income | -130.77M | -144.85M | -119.03M | 220.21M | 182.04M |
Balance Sheet | |||||
| Total Assets | 770.58M | 1.01B | 1.49B | 2.28B | 1.92B |
| Cash, Cash Equivalents and Short-Term Investments | 216.89M | 322.40M | 574.96M | 632.14M | 551.27M |
| Total Debt | 35.58M | 376.69M | 610.97M | 585.26M | 575.22M |
| Total Liabilities | 397.87M | 431.04M | 697.57M | 1.38B | 1.37B |
| Stockholders Equity | 212.38M | 325.29M | 416.75M | 545.22M | 315.50M |
Cash Flow | |||||
| Free Cash Flow | -70.72M | -22.19M | 60.67M | 518.89M | 353.72M |
| Operating Cash Flow | -57.57M | 7.46M | 126.22M | 535.98M | 368.57M |
| Investing Cash Flow | -31.41M | -24.32M | -122.31M | -267.61M | 105.66M |
| Financing Cash Flow | -16.50M | -235.71M | -61.09M | -187.50M | -159.05M |
Maravai Lifesciences Holdings Technical Analysis
Positive
3.56
Price Trends
3.45
Positive
3.41
Positive
2.93
Positive
Market Momentum
-0.04
Negative
61.97
Neutral
82.08
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRVI, the sentiment is Positive. The current price of 3.56 is above the 20-day moving average (MA) of 3.17, above the 50-day MA of 3.45, and above the 200-day MA of 2.93, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 61.97 is Neutral, neither overbought nor oversold. The STOCH value of 82.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRVI.
Maravai Lifesciences Holdings Risk Analysis
Maravai Lifesciences Holdings disclosed 75 risk factors in its most recent earnings report. Maravai Lifesciences Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Maravai Lifesciences Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $759.66M | -3.52 | -65.10% | ― | ― | -5.18% | |
60 Neutral | $1.83B | ― | -41.12% | ― | -16.50% | 33.02% | |
56 Neutral | $1.39B | ― | -29.00% | ― | -27.61% | -69.49% | |
53 Neutral | $910.32M | -3.93 | -48.64% | ― | -30.56% | 48.79% | |
52 Neutral | $921.14M | -20.31 | -17.86% | ― | ― | 8.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.34B | -1.59 | ― | ― | -12.52% | -82.84% |
* Healthcare Sector Average
MRVI
Maravai Lifesciences Holdings
3.56
0.54
17.88%
KURA
Kura Oncology
8.73
1.48
20.41%
IMTX
Immatics
10.34
6.16
147.37%
RLAY
Relay Therapeutics
10.26
7.06
220.62%
IVA
Inventiva
6.49
3.53
119.26%
GHRS
GH Research
14.85
5.64
61.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.